

Supporting Information

Table of Contents

I. General Information.....	S2
II. Preparation of Substrates.....	S3-S7
III. General Experimental Procedures, Spectral Data and HPLC Analysis.....	S7-S18
IV. References.....	S19
V. NMR Spectra.....	S20-S52

I. General Information


a). Materials

All the reactions were carried out in oven-dried Schlenk tubes under argon atmosphere (purity $\geq 99.999\%$). The following chemicals were purchased and used as received: $\text{NiBr}_2 \cdot \text{diglyme}$ (Aldrich), 4,4',4''-tri-tert-butyl-2,2':6',2''-terpyridine (Aldrich), cesium carbonate (99.9%, Aldrich), Anhydrous N,N-Dimethylacetamide (99.8%, HY Scientific), Anhydrous THF (HY Scientific), Anhydrous DMSO (HY Scientific), Anhydrous Toluene (HY Scientific), Anhydrous DMF (Aldrich), Triethoxysilane (95%, TCI), Diethoxymethylsilane (97%, adamas-beta), 1-octyne (95%, TCI), Ethynylcyclopropane (98%, adamas-beta), 3,3-Dimethyl-1-Butyne (95%, adamas-beta), Ethynylcyclohexane (95%, bidepharmatech), 5-Hexynenitrile (98%, Alfa-Aesar), (Trimethylsilyl)acetylene (98%, Alfa-Aesar).

b). Analytical Methods

^1H -NMR, ^{13}C -NMR and ^{19}F -NMR spectra were recorded on a Bruker Avance 400 spectrometer at ambient temperature in CDCl_3 unless otherwise noted; Data for ^1H -NMR are reported as follows: chemical shift (δ ppm), multiplicity, integration, and coupling constant (Hz). Data for ^{13}C -NMR are reported in terms of chemical shift (δ ppm), multiplicity, and coupling constant (Hz). Gas chromatographic (GC) analysis was acquired on a Shimadzu GC-2014 Series GC System equipped with a flame-ionization detector. GC-MS analysis was performed on Thermo Scientific AS 3000 Series GC-MS System. HRMS analysis was performed on Finnigan LCQ advantage Max Series MS System. HPLC analysis was performed on Waters-Breeze (2487 Dual Absorbance Detector and 1525 Binary HPLC Pump). Chiralpak IC, AD, AS, KM columns were purchased from Daicel Chemical Industries, LTD. Organic solutions were concentrated under reduced pressure on a Buchi rotary evaporator. Flash column chromatographic purification of products was accomplished using forced-flow chromatography on Silica Gel (200-300 mesh).


II. Preparation of Substrates



N-(2-iodopropyl)-N-methylaniline CAS:1604039-11-3

^1H NMR (400 MHz, CDCl_3) δ 7.27 – 7.19 (m, 2H), 6.72 (t, J = 7.3 Hz, 1H), 6.65 (d, J = 8.1 Hz, 2H), 4.44 – 4.26 (m, 1H), 3.93 – 3.77 (m, 1H), 3.56 – 3.42 (m, 1H), 2.99 (s, 3H), 1.87 (d, J = 6.8 Hz, 3H).


^{13}C NMR (100 MHz, CDCl_3): δ 148.1, 129.3, 116.9, 111.8, 63.1, 39.8, 25.9, 25.9.



1-(3-iodobutyl)-4-methoxybenzene CAS: 1383841-50-6

^1H NMR (400 MHz, CDCl_3) δ 7.05 (d, J = 8.6 Hz, 2H), 6.76 (d, J = 8.6 Hz, 2H), 4.08 – 3.97 (m, 1H), 3.72 (s, 3H), 2.75 – 2.67 (m, 1H), 2.62 – 2.51 (m, 1H), 2.18 – 2.00 (m, 1H), 1.87 (d, J = 6.8 Hz, 3H), 1.80 – 1.70 (m, 1H).


^{13}C NMR (CDCl_3 , 100 MHz): δ 158.0, 132.8, 129.5, 114.0, 55.3, 44.7, 35.0, 29.9, 29.1.



(3-iodobutyl)benzene CAS: 59456-20-1

^1H NMR (400 MHz, CDCl_3): δ 7.31 – 7.26 (m, 2H), 7.21 – 7.16 (m, 3H), 4.16 – 4.05 (m, 1H), 2.84 – 2.80 (m, 1H), 2.71 – 2.69 (m, 1H), 2.18 – 2.15 (m, 1H), 1.95 (d, J = 6.8 Hz, 3H), 1.92 – 1.82 (m, 1H).


^{13}C NMR (101 MHz, CDCl_3) δ 140.72, 128.50, 128.45, 126.10, 44.38, 35.81, 29.56, 28.96.



3-iodobutyl thiophene-2-carboxylate CAS: 1562423-24-8

^1H NMR (400 MHz, CDCl_3): δ 7.80 (dd, J = 3.7, 1.3 Hz, 1H), 7.55 (dd, J = 5.0, 1.3 Hz, 1H), 7.10 (dd, J = 5.0, 3.8 Hz, 1H), 4.50 (dt, J = 11.3, 5.6 Hz, 1H), 4.35 – 4.25 (m, 2H), 2.27-2.21 (m, 1H), 2.15-2.07 (m, 1H), 2.01 (d, J = 6.9 Hz, 3H).


^{13}C NMR (101 MHz, CDCl_3): δ 161.92, 133.53, 133.51, 132.52, 127.77, 64.79, 41.35, 28.95, 24.00.



3-iodo-1-tosylpyrrolidine: CAS: 919284-59-6

^1H NMR (400 MHz, CDCl_3): δ 7.74 (d, J = 8.19 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.15 – 4.14 (m, 1H), 3.90 (dd, J = 11.7, 5.9 Hz, 1H), 3.55 (dd, J = 11.7, 4.8 Hz, 1H), 3.43 (dd, J = 7.4, 6.1 Hz, 2H), 2.43 (s, 3H), 2.31-2.20 (m, 1H), 2.17-2.07 (m, 1H).


^{13}C NMR (101 MHz, CDCl_3): δ 143.77, 133.91, 129.81, 127.58, 58.63, 46.97, 38.12, 21.55, 17.26.



(4-iodopiperidin-1-yl)(phenyl)methanone CAS: 244240-61-7

^1H NMR (400 MHz, CDCl_3) δ 7.47 – 7.34 (m, 5H), 4.58 – 4.46 (m, 1H), 4.02 – 3.85 (m, 1H), 3.69 – 3.46 (m, 2H), 3.38 – 3.25 (m, 1H), 2.30 – 1.88 (m, 4H).


^{13}C NMR (101 MHz, CDCl_3) δ 170.56, 135.71, 129.83, 128.61, 126.91, 47.71, 42.20, 37.94, 37.16, 26.78.



4-iodo-1-tosylpiperidine CAS: 289890-80-8

^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.33 – 4.22 (m, 1H), 3.20 – 3.12 (m, 2H), 3.05 – 2.88 (m, 2H), 2.44 (s, 3H), 2.17 – 2.06 (m, 4H).


^{13}C NMR (101 MHz, CDCl_3) δ 143.9, 133.5, 129.9, 127.8, 45.8, 36.6, 25.7, 21.7.



4-iodoheptane CAS: 31294-93-6


^1H NMR (400 MHz, CDCl_3) δ 4.27 – 4.01 (m, 1H), 1.93 – 1.77 (m, 2H), 1.70 – 1.61 (m, 2H), 1.59 – 1.51 (m, 2H), 1.47 – 1.36 (m, 2H), 0.93 (t, J = 7.3 Hz, 6H).

^{13}C NMR (101 MHz, CDCl_3) δ 42.88, 40.18, 22.92, 13.41.



ethyl 4-(3-iodopropoxy)benzoate CAS: 211368-04-6


^1H NMR (400 MHz, CDCl_3) δ 8.00 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.9 Hz, 2H), 4.34 (q, J = 7.1 Hz, 2H), 4.08 (td, J = 5.8, 1.3 Hz, 2H), 3.36 (td, J = 6.6, 1.0 Hz, 2H), 2.35 – 2.23 (m, 2H), 1.38 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.48, 162.47, 131.72, 123.31, 114.17, 67.55, 60.82, 32.89, 14.53, 2.30.



N-benzyl-2-bromo-N-phenylbutanamide CAS: 851073-30-8


^1H NMR (400 MHz, CDCl_3) δ 7.43 – 6.92 (m, 10H), 4.90 (s, 2H), 4.07 – 3.84 (m, 1H), 2.26 – 2.09 (m, 1H), 2.05 – 1.78 (m, 1H), 0.89 (t, J = 7.3 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 169.03, 141.11, 136.91, 129.74, 128.88, 128.63, 128.49, 128.38, 127.60, 53.57, 46.04, 28.69, 12.17.



3-cyclopropyl-3-iodopropylbenzene

^1H NMR (400 MHz, CDCl_3) δ 7.31 – 7.25 (m, 2H), 7.22 – 7.17 (m, 3H), 3.44 – 3.33 (m, 1H), 2.95 – 2.84 (m, 1H), 2.79 – 2.67 (m, 1H), 2.30 (m, 1H), 2.20 – 2.04 (m, 1H), 1.49 – 1.38 (m, 1H), 1.00 – 0.88 (m, 1H), 0.78 – 0.67 (m, 1H), 0.44 – 0.34 (m, 1H), 0.27 – 0.10 (m, 1H).




benzyl-(4R)-4-((3S,8R,9S,10S,13R,14S,17R)-3-iodo-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate¹

Prepared using the I₂/PPh₃/imidazole method. ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.28 (m, 5H), 5.15 – 5.06 (m, 2H), 5.03 – 4.97 (m, 1H), 2.40 (ddd, *J* = 15.2, 10.0, 5.0 Hz, 1H), 2.33 – 2.20 (m, 1H), 2.05 – 1.70 (m, 7H), 1.66 – 0.79 (m, 25H), 0.62 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 174.26, 136.26, 128.69, 128.38, 128.33, 66.25, 56.71, 56.13, 42.87, 41.85, 40.30, 39.67, 39.20, 37.08, 35.88, 35.81, 35.46, 32.86, 31.42, 31.11, 28.30, 27.16, 27.06, 26.58, 24.29, 23.81, 20.94, 18.40, 12.18.


HRMS (ESI) calcd for C₃₁H₄₅O₂INa (M+Na⁺):599.2348; found: 599.2349



(3aR,5aR,8aR,8bS)-3a-(iodomethyl)-2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran CAS: 940006-45-1


¹H NMR (400 MHz, CDCl₃) δ 4.58 (dd, *J* = 7.9, 2.5 Hz, 1H), 4.31 (d, *J* = 2.5 Hz, 1H), 4.21 (d, *J* = 7.9 Hz, 1H), 3.89 (d, *J* = 13.0 Hz, 1H), 3.78 (d, *J* = 13.0 Hz, 1H), 3.51 (d, *J* = 10.6 Hz, 1H), 3.33 (d, *J* = 10.6 Hz, 1H), 1.52 (s, 3H), 1.47 (s, 3H), 1.43 (s, 3H), 1.33 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 109.39, 108.60, 100.43, 72.00, 70.85, 70.74, 62.12, 26.69, 26.14, 25.42, 24.35, 10.85.



but-3-yn-1-yl furan-2-carboxylate CAS: 187152-15-4

¹H NMR (400 MHz, CDCl₃) δ 7.61 (m, 1H), 7.34 – 7.15 (m, 1H), 6.52 (m, 1H), 4.48 – 4.17 (m, 2H), 2.73 – 2.41 (m, 2H), 2.08 – 2.05 (m, 1H).




1-bromo-2-(but-3-yn-1-yloxy)-3-(trifluoromethoxy)benzene

¹H NMR (400 MHz, CDCl₃) δ 7.54 (dd, *J* = 10.0, 5.3 Hz, 1H), 6.76 (m, 2H), 4.15 (t, *J* = 7.1 Hz, 2H), 2.77 (td, *J* = 7.1, 2.7 Hz, 2H), 2.11 – 1.99 (m, 1H).


¹⁹F NMR (376 MHz, CDCl₃) δ -57.99.

¹³C NMR (101 MHz, CDCl₃) δ 155.81, 149.23, 133.91, 120.42 (q, *J* = 254.9 Hz), 114.53, 110.33, 107.14, 79.71, 70.54, 67.60, 19.52.



but-3-yn-1-yl 4-fluorobenzoate

^1H NMR (400 MHz, CDCl_3) δ 8.18 – 7.91 (m, 2H), 7.12 (t, J = 8.6 Hz, 2H), 4.42 (t, J = 6.8 Hz, 2H), 2.67 (td, J = 6.7, 2.6 Hz, 2H), 2.05 (t, J = 2.6 Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.10, 164.95 (d, J = 74.7 Hz), 132.23 (d, J = 9.3 Hz), 126.18 (d, J = 3.0 Hz), 115.55 (d, J = 22.0 Hz), 79.97, 70.08, 62.70, 19.09. ^{19}F NMR (376 MHz, CDCl_3) δ -105.43.




but-3-yn-1-yl 3-(trifluoromethyl)benzoate

^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, 1H), 8.24 (t, J = 8.3 Hz, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.59 (dd, J = 9.8, 5.8 Hz, 1H), 4.47 (t, J = 6.8 Hz, 2H), 2.70 (td, J = 6.8, 2.7 Hz, 2H), 2.09 – 2.04 (m, 1H).

^{19}F NMR (376 MHz, CDCl_3) δ -62.89.


^{13}C NMR (101 MHz, CDCl_3) δ 165.14, 131.24 (q, J = 33.0 Hz), 130.94, 129.76 (q, J = 3.6 Hz), 129.24, 126.75 (q, J = 3.9 Hz), 123.78 (q, J = 272.4 Hz), 79.84, 70.35, 63.20, 19.20.



but-3-yn-1-yl 2-bromobenzoate CAS: 1422056-71-0

^1H NMR (400 MHz, CDCl_3) δ 7.83 (dd, J = 7.4, 2.0 Hz, 1H), 7.67 (dd, J = 7.7, 1.4 Hz, 1H), 7.41 – 7.30 (m, 2H), 4.45 (t, J = 6.8 Hz, 2H), 2.69 (td, J = 6.8, 2.6 Hz, 2H), 2.05 (t, J = 2.6 Hz, 1H).


^{13}C NMR (101 MHz, CDCl_3) δ 165.94, 134.53, 132.85, 131.95, 131.60, 127.32, 121.95, 80.03, 70.30, 63.28, 19.12.



but-3-yn-1-yl 2-chlorobenzoate


^1H NMR (400 MHz, CDCl_3) δ 7.91 – 7.79 (m, 1H), 7.54 – 7.38 (m, 2H), 7.32 (td, J = 7.8, 1.7 Hz, 1H), 4.45 (t, J = 6.8 Hz, 2H), 2.68 (td, J = 6.8, 2.6 Hz, 2H), 2.05 (t, J = 2.6 Hz, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 165.43, 133.98, 132.82, 131.64, 131.23, 129.89, 126.71, 80.02, 70.26, 63.18, 19.12.




(but-3-yn-1-yloxy)(tert-butyl)dimethylsilane CAS: 78592-82-2

^1H NMR (400 MHz, CDCl_3) δ 3.67 (t, J = 7.1 Hz, 2H), 2.38 – 2.23 (m, 2H), 1.88 (t, J = 2.7 Hz, 1H), 0.83 – 0.79 (m, 9H), 0.05 – -0.03 (m, 6H).




4-(but-3-yn-1-yloxy)benzaldehyde CAS: 1016536-59-6

^1H NMR (400 MHz, CDCl_3) δ 9.89 (s, 1H), 8.03 – 7.72 (m, 2H), 7.14 – 6.88 (m, 2H), 4.18 (t, J = 6.9 Hz, 2H), 2.73 (td, J = 6.9, 2.7 Hz, 2H), 2.07 (t, J = 2.7 Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 190.93, 163.54, 132.14, 130.34, 114.95, 79.98, 70.40, 66.31, 19.56.




ethyl 4-(but-3-yn-1-yloxy)benzoate CAS: 1493966-83-8

^1H NMR (400 MHz, CDCl_3) δ 8.00 (d, J = 8.3 Hz, 2H), 6.92 (d, J = 8.3 Hz, 2H), 4.35 (q, J = 6.9 Hz, 2H), 4.14 (t, J = 6.8 Hz, 2H), 2.71 (t, J = 6.1 Hz, 2H), 2.06 (s, 1H), 1.38 (t, J = 7.0 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.43, 162.18, 131.69, 123.42, 114.21, 80.16, 70.26, 66.13, 60.81, 19.57, 14.50.



2-(but-3-yn-1-yloxy)tetrahydro-2H-pyran CAS: 40365-61-5

^1H NMR (400 MHz, CDCl_3) δ 4.66 – 4.65 (m, 1H), 3.91 – 3.80 (m, 2H), 3.61 – 3.48 (m, 2H), 2.50 (td, J = 7.0, 2.7 Hz, 2H), 1.97 (t, J = 2.7 Hz, 1H), 1.87–1.80 (m, 1H), 1.76 – 1.68 (m, 1H), 1.61 – 1.51 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ 98.79, 81.45, 69.21, 65.55, 62.24, 30.57, 25.46, 19.98, 19.42.



((but-3-yn-1-yloxy)methyl)benzene CAS: 22273-77-4


^1H NMR (400 MHz, CDCl_3) δ 7.51 – 7.26 (m, 5H), 4.57 (s, 2H), 3.61 (t, J = 6.9 Hz, 2H), 2.51 (td, J = 6.9, 2.7 Hz, 2H), 2.00 (t, J = 2.7 Hz, 1H).

III. General Experimental Procedures, Spectral Data and HPLC

Analysis

Experimental Procedures for Examples Described in Table 1.

In air, catalyst (10%), base (2.5 equiv.), ligand (12%) were added to a Schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three cycles). Solvent was added in turn under argon atmosphere. The reaction mixture was stirred at the room temperature for 5 minutes, 0.2mmol alkyl halide and alkyne (2.0 equiv) was added were added and stirred for 5 minutes, then DEMS (Diethoxymethylsilane, 2.5 equiv) was added. The reaction was stirred at the indicated temperature for 10h. Then the reaction was diluted with EtOAc. Benzophenone was added as an internal standard. The yield was determined by GC.



Entry	Cat.	Ligand	Base	Solvent	T (°C)	Yield (%) ^{3a}
1	NiBr ₂ ·diglyme	dtbpy	NaOAc	DMAC	25	15
2	NiBr ₂ ·diglyme	dtbpy	NaOAc	NMP	25	8
3	NiBr ₂ ·diglyme	dtbpy	NaOAc	DMSO	25	8
4	NiBr ₂ ·diglyme	dtbpy	NaOAc	DMF	25	35
5	NiBr ₂ ·diglyme	dtbpy	K ₂ CO ₃	THF	25	3
7	NiBr ₂ ·diglyme	dtbpy	Na ₂ CO ₃	DMAC	25	17
8	NiBr ₂ ·diglyme	dtbpy	Cs ₂ CO ₃	DMAC	25	65
9	NiBr ₂ ·diglyme	12%dtbpy+15% binap	Cs ₂ CO ₃	DMAC	25	90(84) ⁱ
10	NiBr ₂ ·diglyme	binap	Cs ₂ CO ₃	DMAC	25	8
11	NiBr ₂ ·diglyme	dtbpy	LiOMe	DMAC	25	45
12	NiBr ₂ ·diglyme	dtbpy	KF	DMAC	25	40
13	NiBr ₂ ·diglyme	dtbpy	CsF	DMAC	25	45
14 ^b	NiBr ₂ ·diglyme	dtbpy	Cs ₂ CO ₃	DMAC	25	21
15 ^c	NiBr ₂ ·diglyme	dtbpy	Cs ₂ CO ₃	DMAC	25	20
16 ^d	NiBr ₂ ·diglyme	dtbpy	Cs ₂ CO ₃	DMAC	25	36
17 ^e	NiBr ₂ ·diglyme	dtbpy	Cs ₂ CO ₃	DMAC	25	13
18 ^f	NiBr ₂ ·diglyme	dtbpy	Cs ₂ CO ₃	DMAC	25	trace
19 ^g	-	dtbpy	Cs ₂ CO ₃	DMAC	25	trace
20	Pd(OAc) ₂	PCy ₃	Cs ₂ CO ₃	Toluene	25	6

^a GC yields after 10 hours. ^bTriethoxysilane as Si-H. ^c(Me₂HSi)₂O as Si-H. ^dPh₂SiH₂ as Si-H.

^epolymethylhydrosiloxane as Si-H. ^fEt₃SiH as Si-H. ^gwithout NiBr₂·diglyme. ^hIsolated yield. THF = Tetrahydrofuran, NMP = 1-Methyl-2-pyrrolidinone, DMSO = Dimethyl sulfoxide, DMF = N,N-Dimethylformamide, DMAC = N,N-Dimethylacetamide

Experimental Procedures for Examples Described in Table 2.


In air, NiBr₂·diglyme (10%), Cs₂CO₃ (2.5 equiv.), 12% dtbpy and 15% BINAP were added to a Schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three cycles). 0.6 ml DMAC was added in turn under argon atmosphere. The reaction mixture was stirred at the room temperature for 5 minutes, 0.2 mmol alkyl halide and alkyne (2.0 equiv.) (If they were solid, adding with catalyst together) was added and stirred for 5 minutes, then DEMS (Diethoxymethylsilane, 2.5 equiv) was added. The reaction was stirred at the indicated temperature for 10 h. Then the reaction was diluted with EtOAc, filtered through silica gel with

copious washings. The residue was concentrated, and purified by column chromatography.

Experimental Procedures for Examples Described in Scheme3.

In air, NiBr₂·diglyme (10%), Cs₂CO₃ (2.5 equiv.), dtbpy (12%) and 15% BINAP were added to a Schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three cycles). 20 ml DMAC was added in turn under argon atmosphere. 5 mmol alkyl halide and 7.5 mmol alkyne were added. The reaction mixture was stirred at the room temperature for 5 minutes, then DEMS (Diethoxymethylsilane) was added. The reaction was stirred at the indicated temperature for 10h. Then the reaction was diluted with EtOAc, filtered through silica gel with copious washings. The residue was concentrated, and purified by column chromatography.

Substrate scope




N-methyl-N-(2-methyl-3-methylenenonyl)aniline

Following general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.06 (m, 2H), 6.68 (d, *J* = 7.5 Hz, 3H), 4.80 (m, 2H), 3.42 (dd, *J* = 14.6, 5.8 Hz, 1H), 3.15 (dd, *J* = 14.5, 8.6 Hz, 1H), 2.94 (s, 3H), 2.58 (dd, *J* = 13.9, 6.9 Hz, 1H), 2.03 (d, *J* = 3.9 Hz, 2H), 1.47 – 1.39 (m, 2H), 1.29 (s, 6H), 1.05 (d, *J* = 6.8 Hz, 3H), 0.88 (t, *J* = 6.7 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 153.32, 149.41, 129.24, 115.79, 111.91, 108.69, 59.04, 39.68, 38.39, 35.03, 31.95, 29.35, 28.17, 22.79, 18.22, 14.26.

HRMS (APCI) calcd for C₁₈H₃₀N (M+H⁺): 260.2373; found: 260.2372




(3-methyl-4-methylenedecyl)benzene

Following general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.23 (m, 2H), 7.20 – 7.13 (m, 3H), 4.86 – 4.65 (m, 2H), 2.55 (t, *J* = 8.1 Hz, 2H), 2.16 (dd, *J* = 13.7, 6.9 Hz, 1H), 2.03 – 1.92 (m, 2H), 1.68 – 1.51 (m, 2H), 1.46 – 1.37 (m, 2H), 1.36 – 1.20 (m, 6H), 1.06 (d, *J* = 6.9 Hz, 3H), 0.88 (t, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 154.41, 142.94, 128.39, 128.27, 125.59, 107.66, 39.71, 37.45, 33.82, 33.69, 31.87, 29.33, 28.04, 22.69, 20.24, 14.15.

HRMS (APCI) calcd for C₁₈H₂₉ (M+H⁺): 245.2264; found: 245.2260




3-methyl-4-methylenedecyl thiophene-2-carboxylate

Following general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (dd, *J* = 3.7,

1.2 Hz, 1H), 7.55 (dd, $J = 5.0, 1.1$ Hz, 1H), 7.10 (dd, $J = 4.9, 3.8$ Hz, 1H), 4.83 – 4.70 (m, 2H), 4.36 – 4.15 (m, 2H), 2.38 – 2.26 (m, 1H), 2.02 – 1.96 (m, 2H), 1.88 (dd, $J = 14.1, 7.3$ Hz, 1H), 1.76 (dd, $J = 13.8, 6.9$ Hz, 1H), 1.47 – 1.19 (m, 8H), 1.09 (d, $J = 6.9$ Hz, 3H), 0.88 (t, $J = 6.7$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 162.30, 153.47, 134.07, 133.25, 132.19, 127.71, 108.15, 63.78, 36.67, 34.23, 33.81, 31.83, 29.28, 27.99, 22.66, 20.27, 14.13.

HRMS (APCI) calcd for $\text{C}_{17}\text{H}_{27}\text{O}_2\text{S}$ ($\text{M}+\text{H}^+$): 295.1726; found: 295.1725




3-(oct-1-en-2-yl)-1-tosylpyrrolidine

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.71 (d, $J = 8.2$ Hz, 2H), 7.31 (d, $J = 8.0$ Hz, 2H), 4.72 (m, 1H), 4.63 (m, 1H), 3.52 (dd, $J = 9.4, 7.7$ Hz, 1H), 3.46 – 3.34 (m, 1H), 3.24 (td, $J = 9.6, 6.9$ Hz, 1H), 2.96 (t, $J = 9.5$ Hz, 1H), 2.63 – 2.52 (m, 1H), 2.42 (s, 3H), 2.00 – 1.69 (m, 3H), 1.71 – 1.49 (m, 1H), 1.36 – 1.13 (m, 8H), 0.87 (t, $J = 6.8$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 148.19, 143.37, 134.01, 129.67, 127.50, 109.15, 52.09, 47.63, 43.86, 35.28, 31.71, 30.32, 29.02, 27.86, 22.61, 21.54, 14.09.

HRMS (APCI) calcd for $\text{C}_{19}\text{H}_{30}\text{O}_2\text{NS}$ ($\text{M}+\text{H}^+$): 336.1992; found: 336.1991




N-methyl-N-(2-methyl-3-(trimethylsilyl)but-3-en-1-yl)aniline

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.21 (t, $J = 7.9$ Hz, 2H), 6.65 (t, $J = 7.4$ Hz, 3H), 5.70 (m, 1H), 5.46 (m, 1H), 3.36 (dd, $J = 14.6, 5.3$ Hz, 1H), 3.26 – 3.13 (m, 1H), 2.93 (d, $J = 6.5$ Hz, 3H), 2.77 (dd, $J = 14.3, 6.9$ Hz, 1H), 1.04 (d, $J = 6.8$ Hz, 3H), 0.10 (s, 9H).

^{13}C NMR (101 MHz, CDCl_3) δ 155.98, 149.46, 129.23, 124.33, 115.79, 111.95, 59.41, 39.71, 37.04, 19.60, -0.94.

HRMS (APCI) calcd for $\text{C}_{15}\text{H}_{26}\text{NSi}$ ($\text{M}+\text{H}^+$): 248.1829; found: 248.1832




N-methyl-N-(2,4,4-trimethyl-3-methylenepentyl)aniline

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.23 (dd, $J = 13.5, 5.0$ Hz, 2H), 6.67 (dd, $J = 14.0, 7.7$ Hz, 3H), 5.02 (m, 1H), 4.85 (m, 1H), 3.34 (dd, $J = 14.7, 5.9$ Hz, 1H), 3.24 (dd, $J = 14.7, 9.1$ Hz, 1H), 2.96 (s, 3H), 2.71 (dd, $J = 14.4, 6.9$ Hz, 1H), 1.05 (s, 9H), 0.94 (d, $J = 12.5$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 162.27, 149.36, 129.13, 115.58, 111.68, 106.23, 60.47, 39.73, 36.97, 33.14, 28.74, 21.65.

HRMS (APCI) calcd for $\text{C}_{16}\text{H}_{26}\text{N}$ ($\text{M}+\text{H}^+$): 232.2060; found: 232.2059




4-methyl-5-(methyl(phenyl)amino)-3-methylenepentyl furan-2-carboxylate

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.57 (s, 1H), 7.23 (dd, $J = 13.9, 6.2$ Hz, 2H), 7.16 (d, $J = 3.4$ Hz, 1H), 6.81 – 6.63 (m, 3H), 6.50 (dd, $J = 3.3, 1.6$ Hz, 1H), 4.96 (m, 1H), 4.91 (m, 1H), 4.42 (t, $J = 6.9$ Hz, 2H), 3.41 (dd, $J = 14.6, 6.4$ Hz, 1H), 3.21 (dd, $J = 14.6, 8.1$ Hz, 1H), 2.95 (s, 3H), 2.73 – 2.64 (m, 1H), 2.50 (dd, $J = 13.1, 6.7$ Hz, 2H), 1.08 (d, $J = 6.9$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 158.66, 149.34, 148.37, 146.31, 144.69, 129.16, 117.90, 115.94, 111.91, 111.83, 111.45, 63.58, 58.72, 39.47, 38.60, 33.37, 17.75.


HRMS (APCI) calcd for $\text{C}_{19}\text{H}_{24}\text{O}_3\text{N}$ ($\text{M}+\text{H}^+$): 314.1751; found: 314.1751

**6-methyl-7-(methyl(phenyl)amino)-5-methyleneheptanenitrile**

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.23 (dd, $J = 11.6, 4.3$ Hz, 2H), 6.68 (t, $J = 8.2$ Hz, 3H), 4.93 (m, 1H), 4.84 (m, 1H), 3.40 (dd, $J = 14.6, 6.5$ Hz, 1H), 3.19 (dd, $J = 14.6, 8.0$ Hz, 1H), 2.94 (s, 3H), 2.58 (dd, $J = 14.2, 7.1$ Hz, 1H), 2.32 (t, $J = 7.1$ Hz, 2H), 2.25 – 2.11 (m, 2H), 1.92 – 1.68 (m, 2H), 1.06 (d, $J = 6.9$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 150.65, 149.21, 129.20, 119.64, 116.04, 111.97, 110.34, 58.89, 39.58, 38.12, 33.52, 23.59, 18.09, 16.65.

HRMS (APCI) calcd for $\text{C}_{16}\text{H}_{23}\text{N}_2$ ($\text{M}+\text{H}^+$): 243.1856; found: 243.1851


**4-methyl-5-(methyl(phenyl)amino)-3-methylenepentyl 4-fluorobenzoate**

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 8.03 (dd, $J = 8.1, 6.0$ Hz, 2H), 7.31 – 7.16 (m, 2H), 7.09 (t, $J = 8.5$ Hz, 2H), 6.69 (d, $J = 7.2$ Hz, 3H), 4.95 (m, 2H), 4.43 (t, $J = 6.9$ Hz, 2H), 3.43 (dd, $J = 14.6, 6.3$ Hz, 1H), 3.21 (dd, $J = 14.5, 8.1$ Hz, 1H), 2.95 (s, 3H), 2.67 (dd, $J = 14.0, 7.0$ Hz, 1H), 2.53 (dd, $J = 14.4, 7.5$ Hz, 2H), 1.09 (d, $J = 6.8$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 165.84 (d, $J = 253.7$ Hz), 165.67, 149.31, 148.71, 132.20 (d, $J = 9.3$ Hz), 129.27, 126.64 (d, $J = 2.9$ Hz), 116.08, 115.62 (d, $J = 22.0$ Hz), 112.03, 111.45, 63.72, 58.92, 39.61, 38.57, 33.70, 17.97.

^{19}F NMR (376 MHz, CDCl_3) δ -105.72 (s).

HRMS (APCI) calcd for $\text{C}_{21}\text{H}_{25}\text{O}_2\text{NF}$ ($\text{M}+\text{H}^+$): 342.1864; found: 342.1860


**4-methyl-5-(methyl(phenyl)amino)-3-methylenepentyl 2-chlorobenzoate**

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.79 (dd, $J = 7.7, 1.3$ Hz, 1H), 7.51 – 7.36 (m, 2H), 7.30 (td, $J = 7.7, 1.4$ Hz, 1H), 7.23 (dd, $J = 13.7, 6.4$ Hz, 2H), 6.67 (t, $J = 7.1$ Hz, 3H), 4.96 (m, 2H), 4.53 – 4.37 (m, 2H), 3.42 (dd, $J = 14.6, 6.3$ Hz, 1H), 3.22 (dd, $J = 14.6, 8.1$ Hz, 1H), 2.95 (s, 3H), 2.67 (dd, $J = 14.2, 7.0$ Hz, 1H), 2.61 – 2.42 (m, 2H), 1.09 (d, $J = 6.9$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 165.67, 149.25, 148.48, 133.71, 132.52, 131.35, 131.09, 130.25, 129.18,

126.59, 115.97, 111.95, 111.39, 64.03, 58.79, 39.50, 38.49, 33.48, 17.86.


HRMS (APCI)calcd for C₂₁H₂₅O₂NCl (M+H⁺):358.1568; found: 358.1568



4-methyl-5-(methyl(phenyl)amino)-3-methylenepentyl 2-bromobenzoate

Following general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (dd, *J* = 7.3, 2.0 Hz, 1H), 7.66 (dd, *J* = 7.5, 1.4 Hz, 1H), 7.38 – 7.29 (m, 2H), 7.22 (t, *J* = 7.7 Hz, 2H), 6.69 (d, *J* = 7.1 Hz, 3H), 4.96 (m, 2H), 4.46 (t, *J* = 6.8 Hz, 2H), 3.42 (dd, *J* = 14.5, 6.3 Hz, 1H), 3.22 (dd, *J* = 14.6, 8.1 Hz, 1H), 2.95 (s, 3H), 2.67 (dd, *J* = 13.8, 6.8 Hz, 1H), 2.59 – 2.47 (m, 2H), 1.09 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.15, 149.24, 148.44, 134.36, 132.53, 132.31, 131.26, 129.18, 127.18, 121.68, 115.98, 111.95, 111.41, 64.11, 58.81, 39.51, 38.48, 33.46, 17.87.

HRMS (APCI)calcd for C₂₁H₂₅O₂NBr (M+H⁺):402.1063; found: 402.1063




4-methyl-5-(methyl(phenyl)amino)-3-methylenepentyl 3-(trifluoromethyl)benzoate

Following general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (s, 1H), 8.20 (d, *J* = 7.7 Hz, 1H), 7.81 (d, *J* = 7.7 Hz, 1H), 7.57 (t, *J* = 7.8 Hz, 1H), 7.23 (dd, *J* = 13.1, 5.8 Hz, 2H), 6.67 (dd, *J* = 15.3, 8.3 Hz, 3H), 4.96 (m, 2H), 4.60 – 4.40 (m, 2H), 3.48 – 3.40 (m, 1H), 3.35 – 3.15 (m, 1H), 2.96 (s, 3H), 2.68 (dd, *J* = 14.1, 7.0 Hz, 1H), 2.53 (dt, *J* = 15.5, 7.7 Hz, 2H), 1.10 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 165.21, 149.23, 148.50, 132.79, 131.17, 131.06 (q, *J* = 33.1 Hz), 129.46 (q, *J* = 3.6 Hz), 129.18, 129.09, 126.52 (q, *J* = 3.8 Hz), 123.70 (q, *J* = 272.4 Hz), 116.02, 111.95, 111.48, 64.04, 58.84, 39.51, 38.50, 33.56, 17.86.

¹⁹F NMR (376 MHz, CDCl₃) δ -62.78 (s).

HRMS (APCI)calcd for C₂₂H₂₅F₃NO₂r (M+H⁺):392.1832; found: 392.1831




N-(5-(2-bromo-6-(trifluoromethoxy)phenoxy)-2-methyl-3-methylenepentyl)-N-methylaniline

Following general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.52 (d, *J* = 8.6 Hz, 1H), 7.28 – 7.08 (m, 2H), 6.86 – 6.62 (m, 5H), 4.99 (m, 2H), 4.06 (dd, *J* = 12.2, 6.8 Hz, 2H), 3.44 (dd, *J* = 14.6, 6.7 Hz, 1H), 3.25 (dd, *J* = 14.6, 7.9 Hz, 1H), 2.96 (s, 3H), 2.71 (dd, *J* = 14.0, 7.0 Hz, 1H), 2.59 (t, *J* = 6.8 Hz, 2H), 1.10 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 156.19, 149.33, 149.25, 148.84, 133.74, 129.30, 120.46 (q, *J* = 257.8 Hz), 116.10, 113.92, 112.07, 111.78, 110.10, 106.67, 68.55, 58.91, 39.73, 38.68, 34.02, 18.11.

¹⁹F NMR (376 MHz, CDCl₃) δ -57.89 (s).

HRMS (APCI)calcd for C₂₁H₂₄O₂NBrF₃ (M+H⁺):458.0937; found: 458.0939




N-methyl-N-(2-methyl-3-methylene-5-(((tetrahydro-2H-pyran-2-yl)oxy)pentyl)aniline

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.35 – 6.96 (m, 2H), 6.68 (t, J = 7.5 Hz, 3H), 4.87 (m, 2H), 4.69 – 4.46 (m, 1H), 3.88 (dd, J = 16.2, 8.3 Hz, 2H), 3.57 – 3.46 (m, 2H), 3.45 – 3.36 (m, 1H), 3.19 (dd, J = 14.6, 8.5 Hz, 1H), 2.96 (s, 3H), 2.65 (dd, J = 14.1, 7.0 Hz, 1H), 2.38 (dd, J = 12.1, 6.8 Hz, 2H), 1.83 (dt, J = 9.8, 6.3 Hz, 1H), 1.75 – 1.66 (m, 1H), 1.61 – 1.47 (m, 4H), 1.07 (d, J = 6.9 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 149.68, 149.63, 149.27, 129.13, 115.76, 111.85, 110.45, 99.00, 66.73, 66.67, 62.49, 62.45, 58.65, 39.51, 39.49, 38.87, 34.43, 34.36, 30.76, 30.75, 25.48, 19.71, 19.68, 17.75, 17.74.

HRMS (APCI) calcd for $\text{C}_{19}\text{H}_{30}\text{O}_2\text{N}$ ($\text{M}+\text{H}^+$): 304.2271; found: 304.2273




N-benzyl-2-ethyl-3-methylene-N-phenylnonanamide

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.33 – 7.15 (m, 8H), 6.93 (dd, J = 6.6, 3.0 Hz, 2H), 4.89 (m, 2H), 4.75 (s, 2H), 2.78 (dd, J = 9.1, 5.3 Hz, 1H), 1.94 – 1.78 (m, 2H), 1.77 – 1.66 (m, 1H), 1.59 – 1.46 (m, 1H), 1.32 – 1.08 (m, 8H), 0.85 (dt, J = 13.5, 7.1 Hz, 6H).

^{13}C NMR (101 MHz, CDCl_3) δ 173.05, 148.13, 142.38, 138.00, 129.33, 129.26, 129.02, 128.41, 127.94, 127.36, 110.98, 53.31, 51.60, 34.28, 31.87, 29.24, 27.67, 25.70, 22.74, 14.24, 12.84.

HRMS (APCI) calcd for $\text{C}_{25}\text{H}_{34}\text{NO}$ ($\text{M}+\text{H}^+$): 364.2635; found: 364.2631




N-(5-(tert-butyldimethylsilyl)-2-methyl-3-methylenepentyl)-N-methylaniline

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.34 – 7.09 (m, 2H), 6.79 – 6.52 (m, 3H), 4.85 (m, 1H), 4.80 (d, J = 0.9 Hz, 1H), 3.70 (t, J = 7.3 Hz, 2H), 3.39 (dd, J = 14.6, 6.1 Hz, 1H), 3.15 (dd, J = 14.6, 8.4 Hz, 1H), 2.93 (s, 3H), 2.59 (dd, J = 14.5, 6.9 Hz, 1H), 2.37 – 2.06 (m, 2H), 1.03 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H).

^{13}C NMR (101 MHz, CDCl_3) δ 149.81, 149.38, 129.25, 115.87, 111.95, 110.72, 62.79, 58.83, 39.65, 38.84, 38.01, 26.10, 18.49, 17.91, -5.14.

HRMS (APCI) calcd for $\text{C}_{20}\text{H}_{36}\text{ONSi}$ ($\text{M}+\text{H}^+$): 334.2561; found: 334.2562




(4-(oct-1-en-2-yl)piperidin-1-yl)(phenyl)methanone

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.47 – 7.35 (m, 5H), 4.88 – 4.55 (m, 3H), 4.06 – 3.58 (m, 1H), 3.18 – 2.84 (m, 1H), 2.84 – 2.63 (m, 1H), 2.15 – 2.07 (m, 1H), 2.05 – 1.97 (m, 2H), 1.92 – 1.81 (m, 1H), 1.75 – 1.61 (m, 1H), δ 1.52 – 1.19 (m, 10H), 0.89 (t, J = 6.6 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 170.37, 152.88, 136.42, 129.53, 128.50, 126.93, 108.09, 48.42, 42.82, 42.36, 34.84, 32.07, 31.85, 31.22, 29.23, 28.19, 22.72, 14.18.

HRMS (APCI) calcd for $\text{C}_{20}\text{H}_{30}\text{NO}$ ($\text{M}+\text{H}^+$): 300.2322; found: 300.2318




3-(1-cyclohexylvinyl)-1-tosylpyrrolidine

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, $J = 8.2$ Hz, 2H), 7.33 (d, $J = 8.1$ Hz, 2H), 4.76 (m, 1H), 4.65 (m, 1H), 3.54 (dd, $J = 9.6, 7.6$ Hz, 1H), 3.49 – 3.31 (m, 1H), 3.28 – 3.18 (m, 1H), 2.93 (t, $J = 9.6$ Hz, 1H), 2.68 – 2.58 (m, 1H), 2.44 (s, 3H), 2.00 – 1.84 (m, 1H), 1.77 – 1.42 (m, 7H), 1.29 – 0.82 (m, 5H).

^{13}C NMR (101 MHz, CDCl_3) δ 154.04, 143.47, 134.23, 129.78, 127.62, 107.83, 52.99, 47.74, 43.78, 43.35, 33.09, 33.03, 31.31, 26.82, 26.81, 26.32, 21.66.


HRMS (APCI) calcd for $\text{C}_{19}\text{H}_{28}\text{NO}_2\text{S}$ ($\text{M}+\text{H}^+$): 334.1835; found: 334.1833



4-((3-cyclohexylbut-3-en-1-yl)oxy)benzaldehyde

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 9.88 (s, 1H), 7.83 (d, $J = 8.7$ Hz, 2H), 7.00 (d, $J = 8.8$ Hz, 2H), 4.91–4.69 (m, 2H), 4.14 (t, $J = 7.2$ Hz, 2H), 2.55 (t, $J = 7.2$ Hz, 2H), 1.96 – 1.50 (m, 5H), 1.33 – 0.96 (m, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 190.95, 164.15, 151.05, 132.14, 130.01, 114.94, 109.43, 67.75, 44.78, 34.07, 32.44, 26.85, 26.45.


HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{22}\text{O}_2\text{Na}$ ($\text{M}+\text{Na}^+$): 281.1512; found: 281.1510



Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.99 (d, $J = 8.6$ Hz, 2H), 6.91 (d, $J = 8.5$ Hz, 2H), 4.85 (m, 2H), 4.34 (q, $J = 7.1$ Hz, 2H), 4.14 (t, $J = 7.2$ Hz, 2H), 2.42 (t, $J = 7.2$ Hz, 2H), 2.18 – 1.96 (m, 1H), 1.43 – 1.14 (m, 11H), 0.88 (t, $J = 6.9$ Hz, 6H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.55, 162.72, 148.28, 131.67, 122.94, 114.12, 111.11, 67.15, 60.74, 46.78, 36.26, 31.42, 20.72, 14.52, 14.35.

HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{31}\text{O}_3$ ($\text{M}+\text{H}^+$): 319.2268; found: 319.2260




ethyl 4-((4-methylenedecyl)oxy)benzoate

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.99 (d, $J = 8.9$ Hz, 2H), 6.91 (d, $J = 8.9$ Hz, 2H), 4.76 (m, 2H), 4.35 (q, $J = 7.1$ Hz, 2H), 4.02 (t, $J = 6.4$ Hz, 2H), 2.20 (t, $J = 7.6$ Hz, 2H), 2.12 – 1.99 (m, 2H), 1.99 – 1.80 (m, 2H), 1.50 – 1.33 (m, 5H), 1.30 (dd, $J = 9.5, 4.4$ Hz, 6H), 0.89 (t, $J = 6.7$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.59, 162.91, 149.00, 131.64, 122.83, 114.12, 109.42, 67.74, 60.75, 36.23, 32.25, 31.91, 29.22, 27.86, 27.26, 22.78, 14.53, 14.26.

HRMS (APCI) calcd for $\text{C}_{20}\text{H}_{31}\text{O}_3$ ($\text{M}+\text{H}^+$): 319.2268; found: 319.2267




1-tosyl-3-(1-(trimethylsilyl)vinyl)pyrrolidine

Following general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, $J = 8.2$ Hz, 2H), 7.34 (d, $J = 8.0$ Hz, 2H), 5.46 (m, 1H), 5.31 (d, $J = 1.0$ Hz, 1H), 3.52 (dd, $J = 9.5, 7.4$ Hz, 1H), 3.46 – 3.34 (m, 1H), 3.26 (td, $J = 9.5, 6.9$ Hz, 1H), 2.95 (t, $J = 9.5$ Hz, 1H), 2.69 (dd, $J = 15.9, 8.2$ Hz, 1H), 2.44 (s, 3H), 1.98 – 1.76 (m, 1H), 1.67 – 1.50 (m, 1H), 0.05 (s, 9H).

^{13}C NMR (101 MHz, CDCl_3) δ 150.72, 143.46, 134.11, 129.75, 127.57, 124.44, 53.08, 47.60, 43.40, 31.45, 21.61, -1.12.

HRMS (APCI) calcd for $\text{C}_{16}\text{H}_{26}\text{NO}_2\text{SSi}$ ($\text{M}+\text{H}^+$): 324.1448; found: 324.1445




benzyl (4R)-4-((3R,8R,9S,10S,13R,14S,17R)-3-(4-(benzyloxy)but-1-en-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate.

Following general procedure, as a sticky bubble. The dr was determined to be 5:1 by NMR. The assignment of 3β configuration in the major isomer was based on the large coupling constant at 2.27 ppm, typical of an axial proton in a cyclohexane chair system³.

^1H NMR (400 MHz, CDCl_3) δ 7.43 – 7.11 (m, 10H), 5.11 (d, $J = 2.7$ Hz, 2H), 4.98 – 4.89 (m, 0.29H), 4.82 – 4.66 (m, 2H), 4.59 – 4.42 (m, 2H), 3.68 – 3.51 (m, 2H), δ 2.52 – 2.19 (m, 5H), 2.00 – 1.74 (m, 5H), 1.71 – 1.49 (m, 2H), 1.47 – 1.29 (m, 9H), 1.28 – 1.14 (m, 5H), 1.14 – 0.98 (m, 6H), 0.95 – 0.84 (m, 6H), 0.62 (s, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 174.27, 151.92, 138.61, 136.26, 128.66, 128.49, 128.35, 128.28, 127.81, 127.67, 108.35, 73.08, 69.67, 66.20, 56.58, 56.08, 45.22, 43.91, 42.86, 40.75, 40.28, 37.60, 36.00, 35.45, 35.17, 34.86, 32.88, 31.40, 31.12, 28.31, 27.63, 26.68, 26.65, 24.33, 24.10, 20.96, 18.39, 12.17.

HRMS(ESI) calcd for $\text{C}_{42}\text{H}_{58}\text{O}_3\text{Na}$ ($\text{M}+\text{Na}^+$): 633.4278; found: 633.4273;



2-(1-tosylpiperidin-4-yl)allyl (R)-2-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenoxy)propanoate

Following general procedure, white solid, melting point: 201-213°C.


^1H NMR (400 MHz, CDCl_3) δ 7.86 (d, $J = 2.2$ Hz, 1H), 7.63 (d, $J = 8.2$ Hz, 2H), 7.51 (dd, $J = 9.1, 2.2$ Hz, 1H), 7.31 (d, $J = 8.2$ Hz, 2H), 7.01 – 6.94 (m, 2H), 6.88 – 6.81 (m, 2H), 5.06 (m, 1H), 4.90 (m, 1H),

4.73 (q, $J = 6.8$ Hz, 1H), 4.65 (d, $J = 12.9$ Hz, 1H), 4.54 (d, $J = 12.9$ Hz, 1H), 3.81 (dd, $J = 9.8, 2.0$ Hz, 2H), 2.42 (s, 3H), 2.13 (ddd, $J = 25.2, 12.0, 2.1$ Hz, 2H), 1.76 – 1.65 (m, 3H), 1.61 (d, $J = 6.8$ Hz, 3H), 1.57 – 1.45 (m, 2H).

^{19}F NMR (376 MHz, CDCl_3) δ -134.29.

^{13}C NMR (101 MHz, CDCl_3) δ 171.88, 154.94, 151.37 (d, $J = 11.2$ Hz), 147.08, 147.08 (d, $J = 265.8$ Hz), 145.98, 143.59, 140.28 (d, $J = 6.1$ Hz), 133.16, 129.73, 127.86, 125.21, 125.03, 122.41, 115.93, 113.66, 73.17, 66.88, 46.64, 46.61, 38.50, 30.44, 30.36, 21.64, 18.74.

HRMS(ESI) calcd for $\text{C}_{29}\text{H}_{30}\text{ClFN}_2\text{NaO}_6\text{S}(\text{M}+\text{Na}^+)$: 611.1389; found: 611.1380




2-methyl-4-oxo-3-(2-(1-tosylpiperidin-4-yl)allyl)cyclopent-2-en-1-yl-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxylate

Following general procedure, as a sticky bubble. ($\text{dr} \approx 1:1$). ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, $J = 7.7$ Hz, 2H), 7.31 (d, $J = 7.8$ Hz, 2H), 5.69 (dd, $J = 27.9, 6.0$ Hz, 1H), 4.88 (t, $J = 6.5$ Hz, 1H), 4.73 (m, 1H), 4.56 (m, 1H), 3.84 (d, $J = 11.1$ Hz, 2H), 3.00 – 2.67 (m, 3H), 2.42 (s, 3H), 2.20 (dd, $J = 21.8, 11.4$ Hz, 3H), 2.09 – 2.03 (m, 1H), 1.96 (t, $J = 7.5$ Hz, 3H), 1.82 (d, $J = 12.1$ Hz, 2H), 1.76 – 1.63 (m, 7H), 1.57 (t, $J = 12.1$ Hz, 2H), 1.38 (t, $J = 4.7$ Hz, 1H), 1.31 – 1.20 (m, 3H), 1.13 (d, $J = 3.7$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 204.06, 203.99, 172.37, 172.35, 167.25, 167.16, 148.18, 143.55, 141.45, 141.39, 136.02, 135.19, 133.11, 129.71, 129.67, 127.81, 120.84, 120.77, 109.67, 72.89, 72.62, 46.75, 46.17, 42.05, 41.68, 41.42, 41.39, 34.61, 34.55, 33.33, 33.14, 30.62, 30.59, 29.29, 29.27, 27.95, 27.92, 25.67, 22.24, 22.20, 21.62, 20.60, 20.49, 18.59, 14.30, 14.18.

HRMS(ESI) calcd for $\text{C}_{31}\text{H}_{41}\text{NNaO}_5\text{S}(\text{M}+\text{Na}^+)$: 562.2598; found: 562.2591




2-methyl-4-oxo-3-(2-(((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl)allyl)cyclopent-2-en-1-yl-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxylate

Following general procedure, as a pale-yellow liquid. ($\text{dr} \approx 1:1$). ^1H NMR (400 MHz, CDCl_3) δ 5.72 (dd, $J = 34.6, 5.8$ Hz, 1H), 4.95 (s, 1H), 4.90 (s, 1H), 4.83 (s, 1H), 4.60 (d, $J = 7.8$ Hz, 1H), 4.26 – 4.14 (m, 2H), 3.88 (d, $J = 12.9$ Hz, 1H), 3.73 (d, $J = 12.9$ Hz, 1H), 3.14 (q, $J = 16.0$ Hz, 2H), 2.93 – 2.74 (m, 1H), 2.66 (dd, $J = 13.8, 3.0$ Hz, 1H), 2.46 (d, $J = 13.8$ Hz, 1H), 2.34 – 2.18 (m, 1H), 2.13 – 2.01 (m, 4H), 1.71 (d, $J = 4.0$ Hz, 6H), 1.51 (d, $J = 13.6$ Hz, 6H), 1.36 (d, $J = 9.8$ Hz, 6H), 1.28 (d, $J = 10.1$ Hz, 4H), 1.16 (d, $J = 6.3$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 204.31, 204.18, 172.46, 166.97, 166.86, 141.99, 141.88, 140.28, 140.23, 135.99, 120.94, 120.88, 116.27, 116.17, 109.12, 108.07, 108.05, 103.49, 103.44, 73.08, 73.05, 72.73,

71.01, 70.71, 61.37, 46.59, 46.48, 42.23, 41.86, 34.72, 34.68, 33.27, 33.06, 30.84, 30.79, 29.25, 29.22, 26.67, 26.08, 25.70, 25.30, 24.27, 22.29, 22.23, 20.65, 20.53, 18.63, 14.52, 14.44.

HRMS(ESI) calcd for $C_{31}H_{44}NaO_8(M+Na^+)$: 567.2928; found: 567.2935




(9-(benzyloxy)-7-methylenenon-3-en-1-yl)benzene

Following general procedure, as a pale-yellow liquid. 1H NMR (400 MHz, $CDCl_3$) δ 7.35 – 7.31 (m, 4H), 7.30 – 7.23 (m, 3H), 7.20 – 7.13 (m, 3H), 5.54 – 5.26 (m, 2H), 4.78 (2H), 4.51 (d, J = 2.8 Hz, 2H), 3.69 – 3.24 (m, 2H), 2.76 – 2.53 (m, 2H), 2.45 – 2.16 (m, 4H), 2.15 – 1.88 (m, 4H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 146.29, 142.24, 138.59, 130.43, 129.96, 129.87, 129.17, 128.59, 128.49, 128.39, 128.35, 127.80, 127.67, 125.91, 125.83, 110.73, 73.06, 69.06, 36.39, 36.33, 36.28, 36.25, 36.22, 36.08, 34.56, 30.91, 29.36, 25.64.

HRMS (ESI) calcd for $C_{23}H_{28}NaO$ ($M+Na^+$): 343.2032; found: 343.2030




(5-(4-methoxyphenyl)-3-methylpent-1-en-2-yl)trimethylsilane

Following general procedure, as a pale-yellow liquid. 1H NMR (400 MHz, $CDCl_3$) δ 7.03 – 6.85 (m, 2H), 6.77 – 6.61 (m, 2H), 5.55 – 5.48 (m, 1H), 5.36 – 5.19 (m, 1H), 3.69 (s, 3H), 2.46 (d, J = 7.6 Hz, 2H), 2.31 – 2.13 (m, 1H), 1.71 – 1.57 (m, 1H), 1.55 – 1.42 (m, 1H), 0.94 (dd, J = 17.8, 6.8 Hz, 3H), 0.06 – -0.07 (m, 9H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 157.73, 157.64, 135.16, 129.32, 122.98, 113.83, 55.40, 39.02, 38.69, 33.30, 21.49, -0.72.

HRMS(ESI) calcd for $C_{16}H_{26}NaOSi$ ($M+Na^+$): 285.1645; found: 285.1641




1-(4-bromo-3-methylpent-4-en-1-yl)-4-methoxybenzene

1H NMR (400 MHz, $CDCl_3$) δ 7.09 (d, J = 8.6 Hz, 2H), 6.91 – 6.57 (m, 2H), 5.61 (d, J = 1.4 Hz, 1H), 5.43 (d, J = 1.5 Hz, 1H), 3.78 (s, 3H), 2.60 – 2.52 (m, 1H), 2.49 – 2.41 (m, 1H), 2.37 – 2.31 (m, 1H), 1.87 – 1.69 (m, 1H), 1.64 – 1.49 (m, 1H), 1.10 (d, J = 6.7 Hz, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 157.86, 141.45, 134.19, 129.41, 116.19, 113.86, 55.37, 43.53, 37.00, 32.42, 20.32.

HRMS (ESI) calcd for $C_{13}H_{18}BrO$ ($M+H^+$): 269.0536; found: 269.0533

To a stirred solution of (5-(4-methoxyphenyl)-3-methylpent-1-en-2-yl)trimethylsilane in CH_2Cl_2 (3 mL) at -78 °C was added in the dark a solution of bromine in CH_2Cl_2 . The mixture was stirred for 5 min at -78 °C, gradually warmed to 0 °C, at this temperature and then treated with Na_2SO_3 . The aqueous layer was extracted with CH_2Cl_2 (3 $\times$). The combined organic extracts were washed with brine, dried over anhydrous $MgSO_4$ and concentrated. The crude material was purified with flash chromatography.^{4, 5}




1-(4-iodo-3-methylpent-4-en-1-yl)-4-methoxybenzene

^1H NMR (400 MHz, CDCl_3) δ 7.10 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 6.15 (dd, J = 1.2, 0.7 Hz, 1H), 5.78 (d, J = 1.4 Hz, 1H), 3.79 (s, 3H), 2.59 – 2.47 (m, 1H), 2.47 – 2.41 (m, 1H), 1.83 – 1.74 (m, 1H), 1.69 – 1.59 (m, 1H), 1.54 – 1.45 (m, 1H), 1.00 (d, J = 6.5 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 157.89, 134.21, 129.45, 124.81, 123.28, 113.89, 55.40, 45.69, 38.42, 32.41, 21.76.

HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{18}\text{IO}$ ($\text{M}+\text{H}^+$):317.0397; found: 317.0395

To an anhydrous CH_2Cl_2 (10 mL) solution of (5-(4-methoxyphenyl)-3-methylpent-1-en-2-yl) trimethylsilane was added dropwise a solution of sublimation I_2 in CH_2Cl_2 (10 mL) at 0 °C. After stirring for 30 min, the mixture was stirred for 2 h at r.t., treated with sat. aq $\text{Na}_2\text{S}_2\text{O}_3$ (10 mL). The organic layer was washed with H_2O (2×10 mL), dried (MgSO_4), filtered, and concentrated under vacuum. The residue was purified by column chromatography on silica gel.^{6, 7}




5-(4-methoxyphenyl)-3-methylpentan-2-one⁸


^1H NMR (400 MHz, CDCl_3) δ 7.15 – 6.99 (m, 2H), 6.93 – 6.35 (m, 2H), 3.79 (s, 3H), 2.65 – 2.43 (m, 3H), 2.12 (s, 3H), 2.05 – 1.69 (m, 1H), 1.63 – 1.48 (m, 1H), 1.12 (d, J = 7.0 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 212.78, 157.94, 133.82, 129.38, 113.92, 55.37, 46.52, 34.74, 32.55, 28.26, 16.40.

HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{19}\text{O}_2$ ($\text{M}+\text{H}^+$):207.1380; found: 207.1379



TEMPO	Yield %
0.1 eq	80
0.2 eq	55
0.5 eq	26
1.0 eq	trace



References

- 1.(a).Z. Łotowski, U. Kulesza, A. M. Tomkiel, *Journal of Sulfur Chemistry***2010**, 31, 525-532;
(b).C. M. McMahon, E. J. Alexanian,*Angew. Chem. Int. Ed.* **2014**, 53, 5974-5977; (c).D. Perrone, O. Bortolini, M. Fogagnolo, E. Marchesi, L. Mari, C. Massarenti, M. L. Navacchia, F. Sforza, K. Varani, M. L. Capobianco, *New J. Chem.* **2013**, 37, 3559-3567.
- 2). C. Liu, L. Sun, C. Li, *Journal of Chemical Research***2014**, 38, 309-312
- 3). (a).X. Wu, J. W. T. See, K. Xu, H. Hirao, J. Roger, J. C. Hierro, J. Zhou, *Angew. Chem. Int. Ed.* **2014**, 53, 13573-13577.(b). C. M. McMahon, E. J. Alexanian, *Angew. Chem. Int. Ed.***2014**, 53, 5974-5977. (c).Allevi, P; Anastasia, M.; Ciuffreda, P. Fiecchi, A. Sanvito, A.M. *Steroids.* **1990**, 55, 303.
- 4).G. Landelle, P. A. Champagne, X. Barbeau, J.-F. Paquin, *Org. Lett.* **2009**, 11, 681-684.
- 5). Crich, D. and Lim, L. B. L. 2004. Glycosylation with Sulfoxides and Sulfinates as Donors or Promoters. *Organic Reactions.* 64:2:115–251
- 6).R. Nakajima, C. Delas, Y. Takayama, F. Sato, *Angew. Chem. Int. Ed.* **2002**, 41, 3023-3025.
- 7). M-Z Cai, Z Zhou, P-P Wang,*Synth.***2006**, 5,789-792.
- 8).R. Yamaguchi, H. Kawasaki, M. Kawanisi, *Synth. Commun.* **1982**, 12, 1027-1037.

NMR Spectra

